Hydroxyurea Use in Patients with Sickle Cell Anemia

    Basic Details
    Date Posted
    Tuesday, January 7, 2020
    Status
    Complete
    Medical Product
    hydroxyurea
    Health Outcome(s)
    sickle cell anemia
    use by indication
    Description

    The purpose of this request was to characterize hydroxyurea use among members with sickle cell anemia (SCA). Data from January 1, 2000 to September 30, 2015 from 17 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in these reports. This request was distributed on February 28, 2018. This request contains two reports.

    Report 1 estimated the number patients with SCA, the number of SCA patients who were dispensed hydroxyurea, and the average number of hospitalizations and emergency department visits per person-year among those patients in the SDD. 

    Report 2 examines utilization patterns of hydroxyurea among patients with SCA in the SDD. 

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - September 30, 2015
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)